The Pharmacy Times® Immunization Resource Center is a comprehensive resource for clinical news and expert insights on common immunizations, such as flu, zoster, and COVID-19 vaccines.
May 10th 2024
This is the first approval of an EB virus-related mRNA therapeutic cancer vaccine and is a landmark achievement in future research on cancer treatment.
Reducing Barriers Associated With Pneumococcal Vaccine Uptake
1.5 Credits / Immunization, Infectious Diseases
View More
Reducing the Incidence and Severity of RSV in Older Adults: Opportunities for Patient Identification and Vaccination Counseling
1.0 Credit / Infectious Diseases, Pulmonology/Respiratory
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Diseases, Respiratory, Immunization
View More
Influenza Prevention in the At-Risk Adult Population and the Pharmacist's Role in an Evolving Influenza Vaccine Landscape
1.25 Credits / Immunization, Infectious Disease
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Access, and Adherence
1.5 Credits / HIV/AIDS, Infectious Disease
View More
Study: Linking Flu Vaccination, Potential Cardiovascular Benefits Increases Vaccination Rates
March 9th 2023Vaccination rates were significantly higher in study groups who received a letter highlighting the potential cardiovascular benefits of vaccination and who received repeat letters about the importance of flu vaccination in general.
Read More
Latest Developments in mRNA Technology for Vaccines: Moving Beyond COVID-19
March 2nd 2023Due to the success of mRNA technology with COVID-19, there has been a significant increase in research looking into utilizing mRNA technology, and more specifically, how it can help to advance vaccine development.
Read More
FDA Accepts Biologics License Application for RSV Maternal Vaccine Candidate
February 23rd 2023If approved, the vaccine would be the first immunization for use in pregnant individuals to help protect against the complications of respiratory syncytial virus in infants from birth through 6 months.
Read More